Provider 1619238698
NPI: 1619238698Share
Active Billing Period:2018-01→2024-11(83 months)
Extreme procedure concentration — 58% of $9.3M billed through just 2 codes
Total Paid
$9.3M
$9,298,297
Total Claims
3,159
Beneficiaries
1,949
1.6 claims/patient
Avg Cost/Claim
$3K
Monthly Spending Trend
Yearly Spending
2018
$896K
+5%
2019
$943K
+6%
2020
$995K
+15%
2021
$1.1M
+55%
2022
$1.8M
+16%
2023
$2.0M
-27%
2024
$1.5M
Procedure Breakdown
Cost per claim compared to national benchmarks
This provider bills for 2 distinct procedure codes. The top code (Q5003 (Injection, infliximab-dyyb, biosimilar, 10 mg)) accounts for 58% of total spending.
ProcedureTotalYour Cost/ClaimNational Medianvs MedianPercentile
$5.4M
1,963 claims
$2,759.79
$177.99
15.5×
Top 25%
Q5003Top 25%
Injection, infliximab-dyyb, biosimilar, 10 mg
$5.4M
1,963 claims · 58.3%
Your Cost: $2,759.79/claim|Median: $177.99
15.5× median$3.9M
1,196 claims
$3,244.84
$23.43
138.5×
Top 5%
Q5001Top 5%
Injection, filgrastim-sndz, biosimilar, 1 mcg
$3.9M
1,196 claims · 41.7%
Your Cost: $3,244.84/claim|Median: $23.43
138.5× median